As previously noted, manuscript must conform to the American Medical Association Manual of Style (10th edition). Manuscript title should be concise but informative (do not exceed 75 characters including spaces). Only the first letter of each word in the title should be capitalized – all other letters should be formatted in lower case. The manuscript is in Microsoft Word Windows or Mac, double-spaced, pages numbered, and in a 12-point Times New Roman font.

Original research reports will report new data and include discussions on regulatory implications that best assure linkage and expansion of the science under investigation. The format should be as follows: Abstract, Introduction, Methods, Results, Discussion, Implications for Tobacco Regulation, Human Subjects Approval Statement (when relevant), Conflict of Interest Disclosure Statement, Acknowledgments, References, Tables, and Figures.

The entire abstract should consist of 5 sections (Objectives, Methods, Results, Conclusions, Key words) and not exceed 200 words overall, including all 5 headings. The abstract should state the purpose(s) of the study or investigation, basic procedures, main findings, and the principal conclusions. It should emphasize new and important aspects of the study or observations. Include 4-7 key words or short phrases that will assist in cross-indexing directly after the abstract.

The manuscript should not exceed 5000 words (approximately 18 typed double-spaced pages) excluding the title page, abstract, references, tables, and/or figures. Up to 5 distinct tables and figures (combined) are allowed in total. All pages should be numbered. Where appropriate, indicate use of common methods and measures (see www.PHENX.org). Use Arabic numerals. If the manuscript exceeds these limits, please contact the Editor-in-Chief.

Human Subjects or Animal Approval Statement

Where relevant, include human subjects or animal protection statements indicating institutional review and approval with document number, if possible, or statement of exempt status.

Conflict of Interest Disclosure Statement

Articles published in Tobacco Regulatory Science must be accompanied by a conflict of interest disclosure statement, or a statement that authors have no conflicts of interest to declare (All authors of this article declare they have no conflicts of interest). To execute this policy, all authors must privately disclose to the editors of Tobacco Regulatory Science at the time of their submission ANY and ALL potential conflicts of interest. These include financial and non-financial interests and relationships (see below for definitions), direct employment with a private sector entity (whether full-time, part-time, or on a consultancy basis), and service on private sector and non-profit boards and advisory panels, whether paid or unpaid. Authors also should disclose to editors any conflict of interest that may have influenced either the conduct or the presentation of research, including but not limited to close relationships with those who might be helped or hurt by the publication, academic interests and rivalries, and any personal, religious or political convictions relevant to the topic at hand. In the paper, authors should include a draft statement that discloses all relevant conflicts of interest and affiliations. Relevance for financial conflicts of interest with private firms is defined as a relationship of any value with a firm with a stake in the subject of the manuscript, or its competitors. Relevance for patents is defined as any invention or pending invention connected in any way to one of the authors. Because relevance is often “in the eye of the beholder,” err on the side of full disclosure in drafting the disclosure statement. Editors will check your draft against the private financial disclosure statement, and initiate discussions toward possible adjustments, if necessary.

What to report: Any financial relationship from the past 3 years (dating from the month of submission) of any size should be disclosed. These potential conflicts of interest include:

  • Direct employment, either full or part-time;
  • Grants and research funding (but not grants to your institution or others within your institution on which you did not work); this includes grants from trade associations and non-profits substantially (50% or more) funded by private-sector firms;
  • Consultancies;
  • Travel grants, speaking fees, writing fees, and other honoraria;
  • Paid expert testimony for one side in an adversarial proceeding (this does not include testimony as a factual witness in a civil or criminal case);
  • Patents granted, pending and applications, whether or not generating royalties;
  • Stock ownership, investment in related “sector” funds, or stock options, including those of immediate family members but excluding diversified mutual funds and investment trusts; and
  • Membership on private sector scientific or other advisory boards, whether paid or unpaid.

In addition, any current negotiations regarding future employment or current job offers, either full-time or part-time, must be disclosed.

In disclosing these financial arrangements to editors, authors can include dollar amounts even though they will not be printed in the journal. Editors may choose to exclude this information from publication, but in no case should an editor or author consider an arrangement irrelevant based on its size alone.

Non-Financial Conflicts of Interest: Authors may have strongly-held views about the article being submitted for publication. Authors should consider disclosing and editors may choose to print any affiliations or expressions of these views that may be relevant. These may be personal, political, or intellectual and may include any expression of strongly held views relevant to the subject of the submission. Such disclosures may be original, or they make reference to opinions previously expressed in books or monographs, op-eds or public comments, or to sworn testimony before or lobbying of legislators or legislative bodies. Non-financial conflicts of interest that should be disclosed also include membership or affiliation with non-governmental organizations that have an interest in the submission.

Enforcement

Conflict of interest disclosure relies on the honor system. Editors do not have the time or other resources to be financial auditors or ideological arbiters. Successful disclosure policies depend on the good will and integrity of authors. In all cases of failure to disclose a relevant conflict of interest of which the editors become aware, they will publish an editor’s note that becomes part of the permanent record of that article. In those rare cases where editors uncover a willful desire to conceal financial conflicts of interest, the editors will disallow publication by the author(s) in Tobacco Regulatory Science for a period of up to 3 years.

Acknowledgments

List the sources of support in the form of (1) person(s), grant(s), equipment, or drugs; and (2) note disclaimers, if any, including notices of the manuscript’s prior appearance as a preliminary report, abstract or conference proceedings.

References

References should be numbered consecutively in the order in which they are mentioned in the text. No reference should be given more than one number. Identify references in text by superscript Arabic numerals. Avoid using abstracts as references unless it is available in the public domain. References to papers accepted but not yet published should be designated as “in press”; authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should not be cited. Avoid citing a personal communication unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. Authors should obtain written permission and confirmation of accuracy from the source.

Use the style of the examples below. The titles of journals should be abbreviated according to the style used in Index Medicus (for assistance, see http://www.ncbi.nlm.nih.gov/pubmed/). A period should follow each journal listing and all book titles are italicized. If a journal title does not appear in Index Medicus, the full title should be used. Do not attempt to construct abbreviated titles yourself. For secondary sources, direct quotations, and citations from books or reports, give specific page numbers. Remember; cite personal communications in text only, giving the source and date. If communication is an email: provide sender’s address. References should be listed in the following manner:

Journal Publications of up to 4 Authors (list all 4)

Mumford EA, Pearson JL, Villanti AC, Evans WD. Nicotine and e-cigarette beliefs and policy support among US smokers and nonsmokers. Tob Regul Sci. 2017;3(3):293-304.

Publications of more than 4 Authors (list only 3 followed by et al.)

Russo AR, Solis AC, Villanti AC, et al. Mentoring success in tobacco regulation science: a qualitative study. Tob Regul Sci. 2017;3(3):280-292.

Books

US Food and Drug Administration. Preliminary Scientific Evaluation of the Possible Public Health Effects of Menthol versus Nonmenthol Cigarettes. Silver Spring, MD: Center for Tobacco Products, Food and Drug Administration; 2013.

Quoted Chapter in Books

Eriksen M and Whitney C. Risk Factors: Tobacco. In McQueen DV, Global Handbook on Noncommunicable Diseases and Health Promotion. New York: Springer. 2013, pp 115-136.

Reports

Bruce Ballantine. EPC WORKING PAPER N° 17: Enhancing the role of science in the decision-making of the European Union. European Policy Centre; 2005 (March):1-49.

Web Page

Tobacco Free Kids. Pictorial Warning Labels by Country and Jurisdiction. Pictorial Warning Labels by Country and Jurisdiction (on-line). Available at: http://global.tobaccofreekids.org/en/solutions/international_issues/warning_labels/. Accessed May 24, 2013.

Figures

Number figures consecutively in the order of their first citation in the text. Letters, numbers, and symbols should be clear and even throughout and of sufficient size that each item will still be legible when reduced for publication. Titles and detailed explanations belong in the legends for figures, not embedded in the figures themselves. If a figure has been published, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. Permission is required irrespective of authorship or publisher, except for documents in the public domain. Be sure each figure is cited in text and note where you believe the figure should be placed.

Tables

Insert each table, double-spaced, on a separate page. Number tables consecutively in the order of their first citation in the text and supply a brief but stand alone title for each. Be sure each table is cited in text and note where you believe the table should be placed. Do not use internal horizontal and vertical rules. Place explanatory matter in footnotes, not in the heading. Explain in a separate Note all abbreviations or data descriptions used in each table in alphabetical sequence: a, b, c, d, e, etc. If you use data from another published or unpublished source, obtain permission and acknowledge it fully.

Tables should be on separate pages and appear at the end of the manuscript after the references. Each table width should not exceed 7 inches (18 cm) or 8 columns using 12-point Times New Roman font. Do not embed titles, symbols or formulas into the table. Do not include images of tables in TIFF, PNG, JPEG or PDF formats. Use the Table function in Word to create the table. If unsure the table is acceptable, please e-mail the journal offices and send the proposed table for review prior to submission.

Permissions

It is the responsibility of the author or authors to obtain the necessary permission to use any quoted material in excess of 25 lines that is incorporated in the manuscript. Permission must be obtained, and credit given, for quotations, tables, and illustrations borrowed from copyrighted material. Letters granting permission should accompany the manuscript when submitted.

Abbreviations and Nomenclature

Abbreviations and nomenclature should conform to the American Medical Association Manual of Style (10th edition). Abbreviations should be kept to a minimum in the text and should be defined at first usage. Periods are not used after abbreviations (eg, mm, mL). Generic names are preferred for drugs.

Review Process

To decrease bias during the editorial process, we employ the classic double-blind peer review process. Referees selected are professional scholars in a variety of disciplines including social and behavioral health sciences, health policy, epidemiology, psychology, chemistry, genetics, neuroscience, and other areas relevant to tobacco regulatory science.

  • Upon receipt, a manuscript is assigned a reference number.
  • A copy of the numbered manuscript is electronically sent to a minimum of 3 referees. Referees are selected to match the manuscript with the referee’s area of expertise.
  • Referees evaluate the manuscript according to established criteria on an evaluation form.
  • The Editor-in-Chief transmits reviewer evaluations and comments to the corresponding author, usually within 4 weeks.

Final disposition of the manuscript rests with the Editor-in-Chief.

Plagiarism Prevention Process

Prior to submission, all manuscripts are expected to have been checked for unattributed text via one of several automated software programs (eg, GrammarlyPlagiarismaPaperRateriThenticate, etc).

Impact Factor

An Impact Factor (IF) is not calculated until 2 years after first publication, Tobacco Regulatory Science has submitted appropriate paperwork and should become eligible to receive an IF in 2018.

If additional questions arise, feel to contact the journal offices.